Position in NVAX
as of Jun 30, 2026
· filed Jul 17, 2026
Position Value
$1,629
+$467 QoQ
Shares Held
173
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#224
of 263 holders
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVAX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026MARYLAND CAPITAL ADVISORS INC. holds $43,252 across 15 Biotechnology names. NVAX ranks #2 (3.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
65 | $40,530 | |
| 2 | NVAX |
Novavax Inc
This page
|
173 | $1,629 | |
| 3 | ROIV |
Roivant Sciences Ltd.
|
5 | $176 | |
| 4 | EXEL |
Exelixis, Inc.
|
3 | $163 | |
| 5 | MRNA |
Moderna, Inc.
|
2 | $140 | |
| 6 | BMRN |
Biomarin Pharmaceutical Inc
|
2 | $114 | |
| 7 | INCY |
Incyte Corp
|
1 | $113 | |
| 8 | PTCT |
Ptc Therapeutics, Inc.
|
1 | $81 |
All Filings in NVAX
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,629 | 173 | Shares | Sole | 2026-07-17 | |
| 2025-12-31 | $1,162 | 173 | Shares | Sole | 2026-01-20 | |
| 2025-09-30 | $1,499 | 173 | Shares | Sole | 2025-10-17 | |
| 2025-06-30 | $1,089 | 173 | Shares | Sole | 2025-07-14 | |
| No filing history on record for this holder in this stock. | ||||||